France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
China Inflation Accelerates in August as CPI, PPI Rise 
Global Central Banks Brace for More Rate Hikes as Inflation Risks Rise 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Japanese Yen Nears Seven-Month High as Oil Approaches $100 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
ECB Rate Hike in Focus as Oil Tops $100 
Zara Owner Inditex Sales Rise 9% in August 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Add as a preferred source on Google
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
